InnoCare Pharma Limited (SHA:688428)

InnoCare Pharma Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	6,820	6,241	8,287	8,698	5,929	3,970
Trading Asset Securities	200.19	759.18	-	313.29	317.06	-
Cash & Short-Term Investments	7,020	7,000	8,287	9,011	6,246	3,970
Cash Growth	-0.89%	-15.53%	-8.04%	44.28%	57.34%	67.35%
Accounts Receivable	459.08	351	276.38	127.83	45.27	0.15
Other Receivables	0.66	0.05	31.34	61.79	62.27	78.1
Receivables	459.74	351.05	307.71	189.61	107.55	78.25
Inventory	125.26	95.58	119.09	65.32	9.92	1.88
Other Current Assets	357.93	373.56	51.38	33.56	53.87	42.46
Total Current Assets	7,963	7,820	8,765	9,300	6,417	4,092
Property, Plant & Equipment	755.03	814.27	798.5	937.27	566.08	403.13
Long-Term Investments	2.2	0.4	5.66	11.71	326.1	1.16
Goodwill	3.12	3.12	3.12	3.13	3.13	3.13
Other Intangible Assets	250.1	258.14	266.03	41.31	34.17	37.02
Long-Term Deferred Charges	-	31.94	33.3	-	-	-
Other Long-Term Assets	549.96	479.43	48.06	28.04	50.95	1.05
Total Assets	9,524	9,407	9,920	10,321	7,398	4,538
Accounts Payable	149.97	128.36	134.9	118.6	84.6	5.52
Accrued Expenses	121.02	127.52	100.06	116.03	97.5	50.21
Short-Term Debt	231.96	137.45	-	-	-	-
Current Portion of Long-Term Debt	-	56.35	1,256	1,197	-	-
Current Portion of Leases	-	31.61	23.23	20.11	20.34	6.83
Current Unearned Revenue	35.53	-	-	12	19.48	6.65
Other Current Liabilities	679.48	567.99	567.66	611.52	107.39	35.25
Total Current Liabilities	1,218	1,049	2,082	2,075	329.3	104.45
Long-Term Debt	1,008	1,322	331.88	287.76	1,238	1,150
Long-Term Leases	15.56	27.44	43.65	35.44	47.44	17.17
Long-Term Unearned Revenue	286.96	263	281.78	278.2	123.61	100
Long-Term Deferred Tax Liabilities	-	-	-	-	-	6.04
Total Liabilities	2,846	2,662	2,739	2,677	1,739	1,377
Common Stock	0.02	0.02	0.02	0.02	0.02	0.02
Additional Paid-In Capital	-	12,111	12,150	11,756	9,372	6,743
Retained Earnings	-5,585	-5,520	-5,080	-4,423	-3,536	-3,544
Treasury Stock	-9.01	-3.1	-	-	-	-
Comprehensive Income & Other	12,259	137.99	77.23	263.73	-230.85	-95.05
Total Common Equity	6,665	6,725	7,148	7,597	5,605	3,104
Minority Interest	13.1	20.63	32.86	47.23	54.36	56.49
Shareholders' Equity	6,678	6,746	7,181	7,644	5,659	3,161
Total Liabilities & Equity	9,524	9,407	9,920	10,321	7,398	4,538
Total Debt	1,255	1,575	1,655	1,540	1,306	1,174
Net Cash (Debt)	5,765	5,425	6,632	7,471	4,940	2,796
Net Cash Growth	4.14%	-18.20%	-11.22%	51.24%	76.67%	-
Net Cash Per Share	3.58	3.20	3.89	5.05	3.62	2.89
Filing Date Shares Outstanding	1,822	1,694	1,690	1,682	1,410	1,168
Total Common Shares Outstanding	1,822	1,694	1,690	1,682	1,410	1,168
Working Capital	6,745	6,771	6,683	7,224	6,088	3,988
Book Value Per Share	3.66	3.97	4.23	4.52	3.98	2.66
Tangible Book Value	6,412	6,464	6,879	7,553	5,567	3,064
Tangible Book Value Per Share	3.52	3.81	4.07	4.49	3.95	2.62
Buildings	-	422.73	364.63	224.41	81.04	-
Machinery	-	362.86	302.01	248.13	127.57	13.91
Construction In Progress	-	138.86	166.91	197.65	230.72	296.93
Leasehold Improvements	-	-	-	35.44	6.68	1.08

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.